



September 18, 2020

Company  
Representative Director

Anicom Holdings, Inc.  
Nobuaki Komori

(Securities Code: 8715 TSE 1<sup>st</sup> section)

Inquiries to

Hiroshi Sato  
Corporate Planning Department,  
General Manager

## Notice of the status of our activities, August 2020

The following is a summary of the major targets set as the management targets in Anicom Group's pet insurance business and new business initiatives aimed at realizing the vision of becoming a prevention-oriented company.


Notice of the status of our activities, 2020 (From April 1, 2020 to March 31, 2021)

|  | April                               | May                                 | June                                | July                                | August                              | September              |
|--|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|------------------------|
| Net premiums written*<br>(previous year)   | <b>3,433</b> JPYmn<br>(3,062 JPYmn) | <b>3,660</b> JPYmn<br>(3,274 JPYmn) | <b>3,499</b> JPYmn<br>(3,175 JPYmn) | <b>3,464</b> JPYmn<br>(3,108 JPYmn) | <b>3,577</b> JPYmn<br>(3,188 JPYmn) | JPYmn<br>(3,235 JPYmn) |
| No. of applicants of<br>Doubutsu Kenkatsu<br>(gut microbiota testing)<br>(previous year) | <b>9,290</b><br>(4,725)             | <b>10,611</b><br>(6,580)            | <b>12,770</b><br>(6,455)            | <b>11,572</b><br>(6,601)            | <b>12,545</b><br>(7,492)            | (7,644)                |
| No. of samples for<br>genetic testing<br>(previous year)                                 | <b>8,288</b><br>(9,088)             | <b>7,323</b><br>(10,857)            | <b>9,282</b><br>(11,463)            | <b>10,036</b><br>(13,234)           | <b>9,217</b><br>(16,174)            | (11,945)               |


|  | October                | November               | December               | January                | February               | March                  |
|--|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| Net premiums written*<br>(previous year)   | JPYmn<br>(3,302 JPYmn) | JPYmn<br>(3,230 JPYmn) | JPYmn<br>(3,303 JPYmn) | JPYmn<br>(3,430 JPYmn) | JPYmn<br>(3,296 JPYmn) | JPYmn<br>(3,499 JPYmn) |
| No. of applicants of<br>Doubutsu Kenkatsu<br>(gut microbiota testing)<br>(previous year) | (9,262)                | (8,657)                | (8,427)                | (9,581)                | (10,719)               | (10,806)               |
| No. of samples for<br>genetic testing<br>(previous year)                                 | (13,399)               | (15,703)               | (13,140)               | (14,729)               | (9,934)                | (8,869)                |

(Reference) “Notice of the status of our activities” will be disclosed after middle of each month, but it will be disclosed on the same day as the quarterly earnings announcement date for June, September, December and March.

Net premiums written



No. of applicants of Doubutsu Kenkatsu (gut microbiota testing)



No. of samples for genetic testing

